 ATLANTA--BUSINESS WIRE--Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced dosing of the first patients in its Phase 1 clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinsons disease. This randomized Phase 1 study is investigating the safety, tolerability and pharmacokinetics PK of IkT 